雷公藤内酯三醇 | 137131-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环己烷
• 中文名称: 雷公藤内酯三醇
• 英文名称: triptriolide
• 英文别名: (1S,2S,4S,5R,6S,7R,8S,10S,12S)-5,6,7-trihydroxy-1-methyl-6-propan-2-yl-3,9,15-trioxahexacyclo[10.7.0.02,4.02,8.08,10.013,17]nonadec-13(17)-en-16-one
• CAS: 137131-18-1
• 化学式: C₂₀H₂₆O₇
• 分子量: 378.422
• InChiKey: DYVDZVMUDBCZSA-LZVGCMTRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  雷公藤甲素 以 aq. phosphate buffer 为溶剂， 反应 72.0h， 以34.9%的产率得到雷公藤内酯三醇
  参考文献：
  名称：

  雷公藤甲素衍生物作为潜在的多功能抗阿尔茨海默病药物：合成与结构-活性关系的研究

  摘要：

  由于有希望的神经保护作用和穿越血脑屏障的能力，雷公藤甲素引起了广泛的关注。尽管雷公藤内酯醇有限的溶解度和毒性极大地阻碍了临床翻译，但雷公藤内酯醇已成为阿尔茨海默氏病结构-活性关系研究的有希望的候选者。在本研究中，设计和合成了一系列雷公藤内酯类似物，然后使用细胞培养模型测试了它们的神经保护作用和抗神经炎作用。在测试的雷公藤甲素衍生物中，美金刚共轭物化合物8对Aβ1–42表现出显着的神经保护作用在亚纳摩尔浓度下，对原代皮层神经元培养物的毒性以及对LPS诱导的BV2细胞中TNF-α产生的抑制作用。我们的发现提供了对雷公藤甲素在中枢神经系统中的多功能作用负责的不同药效团的见解。我们的研究应有助于开发基于雷公藤甲素的多功能抗阿尔茨海默病药物。

  DOI：

  10.1016/j.bmcl.2018.01.019

文献信息

• Novel botanical extract of Tripterygium Wilfordii Hook F.
  申请人：Novemed Group Limited

  公开号：US20040018260A1

  公开（公告）日：2004-01-29

  A novel botanical extract from the plant Tripterygium Wilfordii Hook. F. containing bioactive components triptriolide, tripdiolide, tripchloride and tiptolide for treating inflammatory and autoimmune diseases is prepared and the bioactive components are quantified. A HPLC fingerprinting technology is also developed to produce a characteristic fingerprint for the botanical extract.

  从雷公藤植物Tripterygium Wilfordii Hook.F中提取的一种新型植物提取物，包含生物活性成分triptriolide、tripdiolide、tripchloride和tiptolide，用于治疗炎症和自身免疫性疾病，并对生物活性成分进行了定量。还开发了一种HPLC指纹技术，用于生成植物提取物的特征指纹。
• Compositions and methods relating to polycystic kidney disease
  申请人：Somlo Stefan

  公开号：US20080063601A1

  公开（公告）日：2008-03-13

  Described herein are therapeutic strategies (methods and compositions) useful for treating conditions in which cilia are affected and which manifest with cysts and/or fibrosis, such as conditions in which the kidney, pancreas, liver and/or spleen are affected and contain cysts. Particular embodiments described herein are therapeutic strategies in which PC-2 agonists, particularly agonists (calcium channel agonists) that target PC-2 directly and/or selectively, are administered to individuals with mutations in PKD1, in order to alter the course of polycystic kidney disease, particularly ADPKD. In specific embodiments, the invention relates to use of PC-2 agonists triptolide and triptolide derivatives to regulate calcium release. In other aspects, the invention relates to use of PC-2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD1 and/or PKD2, is mutated; calcium signaling is abnormal; or both.
• Treatment of Conditions Caused By Calcium Abnormalities
  申请人：Crews Craig M.

  公开号：US20080188449A1

  公开（公告）日：2008-08-07

  In certain aspects, the invention relates to use of PKD2 agonists, such as triptolide and triptolide derivatives, to regulate calcium release. In other aspects, the invention relates to use of PKD2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD 1 and/or PKD2, is mutated; calcium signaling is abnormal; or both, such as polycystic kidney disease.